Skip to main content
Robert Coleman, MD, Obstetrics & Gynecology, The Woodlands, TX, Memorial Hermann The Woodlands Medical Center

RobertL.ColemanMD

Obstetrics & Gynecology • The Woodlands, TX

Gynecologic Oncology

Chief Scientific Officer, US Oncology Research

Join to view full profile

Dr. Coleman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Coleman's full profile

Already have an account?

Education & Training

  • Creighton University
    Creighton UniversityB.S., Mathematics, 1983
  • University of Texas M D Anderson Cancer Center
    University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1991 - 1993
  • McGaw Medical Center of Northwestern University
    McGaw Medical Center of Northwestern UniversityResidency, Obstetrics and Gynecology, 1987 - 1991
  • Creighton University School of Medicine
    Creighton University School of MedicineClass of 1987

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1992 - 2025
  • IA State Medical License
    IA State Medical License 1994 - 1999
  • American Board of Obstetrics and Gynecology Obstetrics & Gynecology
  • American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

  • Giants of Cancer Care MJH Life Sciences, 2020
  • APGO CREOG Excellence in Teaching APGO CREOG, 2019
  • Margaret Greenfield/Carmel Cohen, MD, Excellence in Ovarian Cancer Research P Gynecologic Cancer Foundation, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer  
    Shannon N Westin, Lois M Ramondetta, Kathleen M Schmeler, Pamela T Soliman, Nicole D Fleming, Jennifer K Burzawa, Alpa M Nick, Andrea M Milbourne, Diane C Bodurka, Rob..., American Journal of Obstetrics and Gynecology
  • Demcizumab Combined with Paclitaxel for Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: The SIERRA Open-Label Phase Ib Trial  
    Robert Coleman, MD, Gynecologic Oncology
  • Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical Cancer  
    Pedro T Ramirez, Robert L Coleman, Michael Frumovitz, The New England Journal of Medicine
  • Join now to see all

Books/Book Chapters

  • 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center 
    Chapter: Ovarian Cancer 
    Coleman RL, Gershenson DMEditors: MA Rodriquez, RS Walters, TW Burke.Springer, New York, NY2013
  • Gynecologic Oncology 
    Chapter: Targeted Therapy and Immunotherapy 
    Coleman R, Sabbatini P2012
  • Textbook of Gynaecological Oncology 
    Chapter: Novel Biologic and Cytotoxic Chemotherapies in Epithelial Ovarian Cancer 
    Moroney, John W and Coleman, Robert LEditors: Ali Ayhan, Nicholas Reed, Murat Gultekin, Polat Dursun.Gunes Publishing, Turkey2011
  • Join now to see all

Abstracts/Posters

  • Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube...
    Coleman RL, Moon J, Sood AK, Delmore JE, Bonebrake AJ, Anderson GL, Alberts DS, Markman M, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2012
  • A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
    B. M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf, K. R. Adler, K. H. Lu, R. L. Coleman, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2011
  • Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
    R. L. Coleman, L. R. Duska, P. T. Ramirez, S. C. Modesitt, K. M. Schmeler, R. Iyer, M. Garcia, A. Sood, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2011
  • Join now to see all

Lectures

  • Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and ... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Unraveling the Risks and Benefits of Antiangiogenic Therapy for Ovarian Cancer Patients 
    UPMC Cancer Center, Pittsburgh, PA, 2015; Hackensack University Medical Center, Hackensack, NJ, 2015 - 1/24/2015
  • Session I: Statistical Design, FDA Drug Approval Procedures; FDA 
    Salt Lake City, UT - 1/20/2015
  • Join now to see all

Other

  • Ovarian Cancer Update: Conversations with Oncology Investigators (Faculty Interview) 
    Coleman RL, Research to Practice
    Miami, FL - 1/1/2011
  • Ovarian Cancer: Answers to the 10 Most Important Questions 
    Coleman RL, Hosted by CancerNet Japan. Sponsored by GOTIC (Gynecologic Oncology Trial and Investigation Consorti
    1/9/2010
  • Recurrent Ovarian Cancer: State of the State 
    Coleman RL, Living Medical Textbook from Projects in Knowledge CME Activity - Oncology Women's Cancers Edition,
    Little Falls, NJ - 1/19/2009
  • Join now to see all

Authored Content

  • SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in ClinicMarch 2023
  • Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020
  • Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020

Press Mentions

  • SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in Clinic
    SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in ClinicMarch 25th, 2023
  • Maintenance Therapy the 'Biggest Breakthrough in Decades' for Ovarian Cancer
    Maintenance Therapy the 'Biggest Breakthrough in Decades' for Ovarian CancerSeptember 15th, 2022
  • Health Care Giants McKesson and HCA Partner up in Cancer Research Joint Venture
    Health Care Giants McKesson and HCA Partner up in Cancer Research Joint VentureJune 23rd, 2022
  • Join now to see all

Grant Support

  • Uterine SPORE Project 3NCI2004–2016
  • Ovarian SPORE - Project 2NCI2004–2016
  • EpharnaCPRIT2011–2015

Professional Memberships

Hospital Affiliations

Dr. Robert Coleman, Dr. Robert Coleman, MD, Dr. R Coleman, Dr. Robert L. Coleman